Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
companyunderground
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
»
companies
» Eli Lilly
Eli Lilly
57 Million Eligible For GLP-1 Drug Coverage In U.S. And That’s Just Those Under 65
Forbes
Thu, 09/5/24 - 10:29 pm
obesity
GLP-1
Novo Nordisk
Eli Lilly
Ozempic
Wegovy
insurers
Eli Lilly says experimental insulin could mean 313 fewer injections per year
Quartz
Thu, 09/5/24 - 11:50 am
Eli Lilly
long-acting insulin
diabetes
clinical trials
efsitora
Eli Lilly partners with AI-focused Genetic Leap to develop RNA-based drugs
Reuters
Thu, 09/5/24 - 11:38 am
Eli Lilly
Genetic Leap
drug development
artificial intelligence
BioAge files for IPO, plans pair of midstage obesity trials
Fierce Biotech
Wed, 09/4/24 - 11:40 am
BioAge Labs
IPOs
Eli Lilly
obesity
clinical trials
Eli Lilly bets $1B in biobucks on Haya to scour dark genome for obesity targets
Fierce Biotech
Wed, 09/4/24 - 11:37 am
Eli Lilly
Haya Therapeutics
dark genome
obesity
drug discovery
New research could ease concerns over suicide risk of obesity drugs
BioPharma Dive
Tue, 09/3/24 - 05:58 pm
obesity
suicide
GLP-1
Novo Nordisk
Eli Lilly
Ozempic
Wegovy
Mounjaro
Zepbound
Eli Lilly partner Hutchmed scraps China stomach cancer filing as approval seems unlikely
Fierce Pharma
Fri, 08/30/24 - 11:40 am
Hutchmed
Eli Lilly
Fruzaqla
China
stomach cancer
Eli Lilly’s lauded discount of its obesity drug Zepbound comes with caveats
Stat
Wed, 08/28/24 - 09:24 pm
Eli Lilly
Zepbound
DTC
Eli Lilly rolls out direct patient access to weight loss star Zepbound—at a deep discount
Fierce Pharma
Tue, 08/27/24 - 11:51 am
Eli Lilly
Zebound
DTC
Lilly launches smallest single-dose vials of Zepbound for $399
Reuters
Tue, 08/27/24 - 11:16 am
Eli Lilly
Zepbound
Mixed reactions among HCPs as lecanemab and donanemab secure FDA approval for Alzheimer's treatment
Pharmaphorum
Mon, 08/26/24 - 10:14 am
Alzheimer's disease
physicians
Eli Lilly
Kisunla
donanemab
lecanemab
Eli Lilly seeks new angle on high-value target, tapping Oblique for antibody discovery push
Fierce Biotech
Thu, 08/22/24 - 11:55 am
Eli Lilly
Oblique Therapeutics
AbiProt
drug discovery
antibodies
Lilly’s tirzepatide cuts diabetes risk, study data show
BioPharma Dive
Tue, 08/20/24 - 11:54 am
Eli Lilly
tirzepatide
Mounjaro
Zepbound
type 2 diabetes
diabetes
clinical trials
After Europe deal, Organon pays $22.5M to expand Emgality marketing pact with Lilly
Fierce Pharma
Tue, 08/20/24 - 11:34 am
Organon
Europe
Eli Lilly
Emgality
Rayvow
migraines
'We're pretty prolific': Lilly Catalyze360 looks to connect with emerging biotechs across 'all areas'
Fierce Biotech
Mon, 08/19/24 - 11:10 am
Eli Lilly
Lilly Catalyze360
innovation
business development
Forget Mounjaro: Eli Lilly's Next Big Blockbuster Has Arrived
Motley Fool
Sun, 08/18/24 - 09:19 pm
Eli Lilly
FDA
obesity
Zepbound
IRA negotiations slash Medicare prices for Big Pharma blockbusters by up to 79%
Fierce Pharma
Thu, 08/15/24 - 11:55 am
Medicare
drug pricing
Inflation Reduction Act
JNJ
Xarelto
Imbruvica
Stelara
Bristol Myers Squibb
Eliquis
Eli Lilly
Jardiance
Merck
Januvia
Amgen
Enbrel
AstraZeneca
Farxiga
Novo Nordisk
Fiasp
Novartis
Entresto
Lilly demands doctors stop selling copycat weight-loss drugs
Reuters
Thu, 08/15/24 - 11:50 am
Eli Lilly
drug counterfeiting
Zepbound
weight loss
Eli Lilly unwraps $700M nucleic acid R&D center in Boston Seaport, opens doors to biotechs
Fierce Biotech
Tue, 08/13/24 - 11:49 am
Eli Lilly
Boston
R&D
DNA
RNA
Weight-loss drugs like Wegovy may help stave off some cancers
NPR
Mon, 08/12/24 - 11:28 am
cancer
GLP-1 agonist
Wegovy
Zepbound
Novo Nordisk
Eli Lilly
Pages
« first
‹ previous
…
4
5
6
7
8
9
10
11
12
…
next ›
last »